GlassScriptPhysician profile
Adesua Wejinya
NPI 1790812246
$9,527.20
in general payments reported to CMS, 2019-2025
31 companies · $1,759 in 2025
The $1,759 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,825 · 2020: $584 · 2021: $1,379 · 2022: $1,549 · 2023: $1,124 · 2024: $1,307 · 2025: $1,759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,946 · Education: $227 · Consulting Fee: $16.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,945.81 |
| Education | $227.47 |
| Consulting Fee | $16.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $1,507.63 | 2019-2025 | Xolair |
| Genzyme Corporation | $1,230.41 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,127.50 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $824.62 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $687.13 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Regeneron Healthcare Solutions, INC. | $465.67 | 2019-2025 | Dupixent |
| Shire North American Group INC | $460.75 | 2019 | |
| Csl Behring | $409.19 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Novartis Pharmaceuticals Corporation | $355.61 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $338.72 | 2021-2025 | |
| Grifols USA, LLC | $335.85 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Pharming Healthcare, INC. | $262.20 | 2019-2025 | Ruconest |
| Amgen INC. | $254.39 | 2021-2024 | Tezspire |
| Ars Pharmaceuticals Operations, INC. | $249.47 | 2025 | Neffy |
| Octapharma USA, INC. | $243.42 | 2019-2025 | Octagam Immune Globulin (Human) |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $157.17 | 2019-2023 | Auvi-Q |
| Pfizer INC. | $124.09 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $115.05 | 2021-2024 | Orladeyo |
| Ionis Pharmaceuticals, INC. | $53.62 | 2025 | Dawnzera, Donidalorsen |
| Lilly USA, LLC | $41.99 | 2024-2025 | Ebglyss |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.19 | 2019-2021 | |
| Adma Biomanufacturing LLC | $32.80 | 2021-2025 | |
| Bio Products Laboratory USA, INC. | $31.62 | 2021-2022 | |
| Galderma Laboratories, L.P. | $31.15 | 2025 | Nemluvio |
| Abbvie INC. | $27.67 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $26.05 | 2021 | |
| Hospira, INC. | $23.88 | 2024 | |
| Organon LLC | $21.05 | 2025 | Vtama, Nexplanon |
| Kowa Pharmaceuticals America, INC. | $17.43 | 2025 | Zoryve |
| Gc Biopharma USA, INC. | $15.11 | 2025 | Alyglo |
| Merck Sharp & Dohme LLC | $14.77 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adesua Wejinya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.